These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15345269)

  • 1. Rats on the grog: novel pharmacotherapies for alcohol craving.
    McGregor IS; Gallate JE
    Addict Behav; 2004 Sep; 29(7):1341-57. PubMed ID: 15345269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.
    Gallate JE; Mallet PE; McGregor IS
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):210-6. PubMed ID: 14663553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats.
    Hargreaves GA; McGregor IS
    Alcohol Clin Exp Res; 2007 Nov; 31(11):1900-7. PubMed ID: 17877781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.
    Manzanares J; Ortiz S; Oliva JM; Pérez-Rial S; Palomo T
    Alcohol Alcohol; 2005; 40(1):25-34. PubMed ID: 15550451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic approaches to the management of alcoholism.
    Anton RF
    J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism.
    Valdez GR; Koob GF
    Pharmacol Biochem Behav; 2004 Dec; 79(4):671-89. PubMed ID: 15582675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716.
    Gallate JE; McGregor IS
    Psychopharmacology (Berl); 1999 Mar; 142(3):302-8. PubMed ID: 10208323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Spanagel R; Zieglgänsberger W
    Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
    Kato H
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2008 Oct; 43(5):697-704. PubMed ID: 19068776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medications and alcohol craving.
    Swift RM
    Alcohol Res Health; 1999; 23(3):207-13. PubMed ID: 10890816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Craving for alcohol: findings from the clinic and the laboratory.
    Sinha R; O'Malley SS
    Alcohol Alcohol; 1999; 34(2):223-30. PubMed ID: 10344782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological validation of a new animal model of alcoholism.
    Spanagel R; Hölter SM
    J Neural Transm (Vienna); 2000; 107(6):669-80. PubMed ID: 10943907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Heilig M; Egli M
    Pharmacol Ther; 2006 Sep; 111(3):855-76. PubMed ID: 16545872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study.
    Kwako LE; Spagnolo PA; Schwandt ML; Thorsell A; George DT; Momenan R; Rio DE; Huestis M; Anizan S; Concheiro M; Sinha R; Heilig M
    Neuropsychopharmacology; 2015 Mar; 40(5):1053-63. PubMed ID: 25409596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
    O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
    Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutics for alcoholism: what's the future?
    Lawrence AJ
    Drug Alcohol Rev; 2007 Jan; 26(1):3-8. PubMed ID: 17364830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone in alcohol dependence.
    Hartmann PM
    Am Fam Physician; 1997 Apr; 55(5):1877-9, 1883-4. PubMed ID: 9105212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone.
    Zalewska-Kaszubska J; Gorska D; Dyr W; Czarnecka E
    Physiol Behav; 2008 Mar; 93(4-5):1005-10. PubMed ID: 18262210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABA(A) and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviors.
    Foster KL; McKay PF; Seyoum R; Milbourne D; Yin W; Sarma PV; Cook JM; June HL
    Neuropsychopharmacology; 2004 Feb; 29(2):269-84. PubMed ID: 14666116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.